In a report released today, William Tanner from Cantor Fitzgerald maintained a Buy rating on Supernus Pharmaceuticals (NASDAQ: SUPN), with a price target of $56. The company’s shares opened today at $47.95.
Tanner noted:
“We anticipate the core Trokendi XR and Oxtellar XR businesses will continue to perform well, particularly the former, with the ongoing roll-out for the migraine prevention indication. Over the next 12-24 months, with provision of positive clinical trial data, we believe investors will better appreciate the value of pipeline assets SPN-810 and SPN-812 and the bipolar indication opportunity for Oxtellar XR.”
According to TipRanks.com, Tanner is a 3-star analyst with an average return of 1.8% and a 47.5% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Evofem Biosciences Inc, and Amag Pharmaceuticals.
Currently, the analyst consensus on Supernus Pharmaceuticals is a Strong Buy with an average price target of $54.75.
See today’s analyst top recommended stocks >>
Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $30.74 million. In comparison, last year the company had a net profit of $15.96 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
